- 现金
- 222032 元
- 精华
- 285
- 帖子
- 67620
- 注册时间
- 2001-11-10
- 最后登录
- 2023-5-7
|
7楼
发表于 2002-8-24 22:10
可可: 对于肝癌术后病人, 现在有一种新型药物食品: Active hexose correlated compound (缩写: AHCC), 据说可以提高自然杀伤细胞的活力, 甚至可能被用来作为生物反应"修整物"来治疗癌症患者. 由于缺乏治疗癌症的临床实用/试验数据, 一组日本医生对于手术后的癌症病人进行了此药物的试用, 结果和诊断评估都是好的. 我不能将这个发出作为治疗癌症的药物, 但是就第一名肝癌手术后的病人在昨晚化疗后, 或有剧烈反应时, 不妨也是一个询问医生的希望和来源. 麻烦你转过去, 我都不知道那个网站在那里. 谢谢.
原文简摘:
JULY 2002 HEPATOCELLULAR CARCINOMA -Improved Prognosis of Postoperative Hepatocellular Carcinoma Patients When Treated with Functional Foods: A Prospective Cohort Study
Y.Matsui , J. Uhara, S. Satoi, M. Kaibori, H. Yamada, H. Kitade, A. Imamura, S. Takai, Y. Kawaguchi, A.Kwon,Y.Kamiyama
First Department of Surgery, Kansai Medical University, , Moriguchi, Osaka, Japan
Background/Aims: Active hexose correlated compound (AHCC) is a newly developed functional food. In vitro experiments have shown that AHCC enhances natural killer cell activity, and may be considered a potent biological response modifier in the treatment of cancer patients. However, the effects of AHCC in a clinical setting have not been reported. We seek to determine whether AHCC can improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment.
Methods: A prospective cohort study was performed from February 1, 1992 to December 31, 2001. A total of 269 consecutive patients with histologically confirmed HCC were studied. All of the patients underwent resection of a liver tumor. Time to treatment failure (disease recurrence or death) and ten parameters related to liver function after surgery were examined.
Results: Of the 269 patients, 113 received AHCC orally after undergoing curative surgery (AHCC group). The AHCC group had a significantly longer no recurrence period (hazard ratio (HR), 0.639; 95% confidence interval (CI), 0.429-0.952; P=0.0277) and an increased overall survival rate (HR, 0.421; 95% CI, 0.253-0.701; P=0.0009) when compared to the control group by Cox's multivariate analysis.
Conclusions: This study suggests that AHCC intake can improve the prognosis of postoperative HCC patients.
(J. Hepatol., 37 , 78-86,2002)
(引用本文, 翻译, 采用内容, 敬请注明出处和作者们)
|
|